MIVT (India) is the fully owned subsidiary of MIV Therapeutics Inc Canada which is an advanced stage R & D company rapidly progressing towards commercializing the next generation of fully biocompatible coatings for passive & drug eluting application on cardiovascular stents & other medical devices.
MIVT (India)’s Metallic Stent “genX & genX Cr-Co are designed carefully to incorporate controlled stent expansion characteristics, better stent-artery compliance, superior acute gain, optimum cell size & shape , Lower strut thickness and high flexibility.
MIVT (India)’s having another product Protea™ Chromium Cobalt Coronary Stent is next generation uniform sinusoidal strut design with controlled stent expansion characteristics, better stent-artery compliance, superior acute gain, optimum cell size & shape , Lower strut thickness and high flexibility.
MIVT (India)’s “GenXSync” ultra thin drug-eluting stent uses a biodegradable polymer and anti-immunosuppressive drug on the Protea™ platform.
MIVT (India)’s “VestaSync” drug-eluting stent developed a unique new coating technology that uses Hydroxyapatite (HAp) as a drug career. This proprietary, patented coating will prove to have superior biocompatibility & drug eluting characteristics. |
